PTCH1 germline pathogenic variants cause Nevoid Basal Cell Carcinoma Syndrome (NBCCS / Go...
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | BMA-PTCH1-GERMLINE-NBCCS-GORLIN |
|---|---|
| Тип | Клінічна застосовність |
| Статус | переглянуто 2026-05-18 | очікує клінічного підпису | потрібне рев’ю клінічної застосовності |
| Хвороби | DIS-BCC |
| Джерела | SRC-NCCN-SKIN-2025 |
Дані про клінічну застосовність
| Біомаркер | BIO-PTCH1-GERMLINE |
|---|---|
| Варіант | PTCH1 germline pathogenic (NBCCS / Gorlin syndrome) |
| Хвороба | DIS-BCC |
| Рівень ESCAT | IIA |
| Рекомендовані комбінації | vismodegib 150 mg PO daily — locally advanced / metastatic BCC; off-label BCC-burden reduction in NBCCS (intolerance of recurrent surgery), sonidegib 200 mg PO daily — locally advanced BCC; off-label NBCCS BCC-burden reduction, topical 5-fluorouracil / imiquimod — superficial BCC field therapy adjunct, dermatology q3-6mo with photodynamic therapy / curettage for low-risk lesions; Mohs for high-risk sites, oral/maxillofacial surgery follow-up for odontogenic keratocyst (recurrence-prone — marsupialization vs enucleation), minimize EBRT exposure (BCC induction in irradiation field is a known late effect) |
| Протипоказана монотерапія | external-beam radiation therapy for medulloblastoma when alternatives available — induces BCCs in field (NBCCS-specific concern) |
| Підсумок доказів | PTCH1 germline pathogenic variants cause Nevoid Basal Cell Carcinoma Syndrome (NBCCS / Gorlin syndrome) — characterized by multiple early-onset basal cell carcinomas (BCCs, often hundreds over a lifetime), odontogenic keratocysts of the jaw, palmar/plantar pits, macrocephaly, rib + skeletal anomalies, cardiac fibroma, and ~5% lifetime risk of desmoplastic-type medulloblastoma (SHH subgroup) — peak age 1-2 years. Confirmed-carrier surveillance protocol (per Bree & Shah 2011 / NCCN Skin): pediatric brain MRI q6mo from diagnosis through age 3 then annually through age 7 (medulloblastoma); whole-body dermatology q6mo from infancy for BCC detection (transition to q3mo after first BCC); jaw OPG / panoramic radiograph q1y from age 8 for odontogenic keratocyst; echocardiogram in infancy for cardiac fibroma; minimize ionizing radiation exposure (BCCs induced by EBRT — avoid radiotherapy for medulloblastoma when alternatives available). Vismodegib and sonidegib (Hedgehog-pathway smoothened inhibitors) are active for locally advanced/metastatic BCC and for BCC-burden reduction (off-label), sur... |
Нотатки
STUB — Wave A+B germline expansion. Linked Indication: none (no Gorlin/ NBCCS-specific Indication exists yet). Two-Clinical-Co-Lead signoff queued. PTCH1 carriers face the BCC-treatment paradox: surgical excision is gold standard but cumulative scarring + functional impairment make Hedgehog- pathway inhibitors attractive for diffuse disease — vismodegib drug-holiday protocols (3 mo on / 3 mo off) attempt to balance efficacy with muscle cramps, alopecia, dysgeusia, weight loss. SUFU germline (BMA-SUFU-GERMLINE- MEDULLOBLASTOMA) is the alternate NBCCS-like locus.
Де використовується
У YAML-корпусі не знайдено зворотних посилань.